Hal Martin, MD, MPH

Exec Director, Virology Clinical Research
Gilead Sciences Inc.
Foster City, California, United States

Gilead Sciences Inc. (Employee, Shareholder)

Presentation(s):

• 69 - Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks

  On Demand